Limits...
An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation.

Zhang X, Liu Q, Hu J, Xu L, Tan W - Acta Pharm Sin B (2014)

Bottom Line: A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C.Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer.The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.

View Article: PubMed Central - PubMed

Affiliation: School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China.

ABSTRACT
An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.

No MeSH data available.


Related in: MedlinePlus

© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4590724&req=5


An aerosol formulation of R-salbutamol sulfate for pulmonary inhalation.

Zhang X, Liu Q, Hu J, Xu L, Tan W - Acta Pharm Sin B (2014)

© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4590724&req=5

Bottom Line: A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C.Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer.The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.

View Article: PubMed Central - PubMed

Affiliation: School of Bioscience and Bioengineering, South China University of Technology, Guangzhou 510006, China.

ABSTRACT
An aerosol formulation containing 7.5 mg of R-salbutamol sulfate was developed. The aerosol was nebulized with an air-jet nebulizer, and further assessed according to the new European Medicines Agency (EMA) guidelines. A breath simulator was used for studies of delivery rate and total amount of the active ingredient at volume of 3 mL. A next generation impactor (NGI) with a cooler was used for analysis of the particle size and in vitro lung deposition rate of the active ingredient at 5 °C. The anti-asthmatic efficacy of the aerosol formulation was assessed in guinea pigs with asthma evoked by intravenous injection of histamine compared with racemic salbutamol. Our results show that this aerosol formulation of R-salbutamol sulfate met all the requirements of the new EMA guidelines for nebulizer. The efficacy of a half-dose of R-salbutamol equaled that of a normal dose of racemic salbutamol.

No MeSH data available.


Related in: MedlinePlus